Cradle

Cradle is productizing generative protein engineering as accessible SaaS — the layer that turns AI protein design from a specialist research project into everyday R&D infrastructure. Its web-based platform pairs generative ML models with each customer's own wet-lab data, proposing sequence variants and learning across iterative design rounds to optimize proteins for stability, activity, and expression, deliberately built so that biologists without machine-learning backgrounds can run AI-guided engineering. The go-to-market is validated by a customer roster most tools companies would envy: Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis, and Grifols, with reported 1.2x-to-12x R&D speedups across therapeutics, diagnostics, agriculture, chemicals, and food. The horizontal breadth is the point — the same platform sells into medicines, industrial enzymes, food ingredients, and bioplastics, giving Cradle a far larger addressable market than any single-vertical drug-design shop. Backing is strong for a SaaS-model biotech: a $73M Series B in November 2024 led by IVP with Index Ventures and Kindred Capital, for more than $100M raised total, funding wet-lab expansion, engineering, and go-to-market scaling. If protein engineering follows the trajectory of other software categories — where the accessible, self-serve tool that any lab can adopt wins the long tail while bespoke consulting shops fight over the head — Cradle's neutral-arms-dealer positioning across every protein-using industry is a durable, capital-efficient franchise.

Cradle's accessibility thesis cuts against its defensibility: a self-serve protein-design tool is easier to sell but harder to lock in, and the underlying models are commoditizing fast as open-weight protein language models, structure predictors, and generative designers proliferate — every improvement in freely available AlphaFold-, ESM-, and diffusion-class models raises the floor for competitors and lowers customers' willingness to pay for a wrapper. The moat has to come from proprietary data and the closed design-build-test loop, but Cradle largely relies on customers' own wet-lab measurements, which means the most valuable data accrues to the customer, not necessarily to a defensible shared model. Competition is dense and well-funded on all sides: Generate Biomedicines, Chai, and Absci pursue therapeutics with deeper pharma integration; incumbents like Ginkgo and the enzyme majors serve industrial customers; and the largest customers (Novo, J&J) have every incentive to build internal capability once the workflow is understood, turning today's marquee logos into tomorrow's churned accounts. Horizontal breadth also dilutes focus — supporting therapeutics, food, agriculture, and materials means competing against a different specialist in each, none of which Cradle can out-resource. The reported R&D-speedup range (1.2x to 12x) is wide enough to suggest inconsistent value delivery. At $100M raised, Cradle is priced as a category leader in a category whose core technology is being given away, and SaaS economics only work if the switching costs prove real.